Monograph: |
FIMASARTAN POTASSIUM
FIMASARTAN IS AN ANGIOTENSIN II RECEPTOR ANTAGONIST (ARB) DRUG EMPLOYED IN THE TREATMENT OF BOTH HYPERTENSION AND HEART FAILURE. IT HAS BEEN FOUND TO BE SAFE WHEN ADMINISTERED WITH HYDROCHLOROTHIAZIDE (A DIURETIC) IN CLINICAL TRIALS. FIMASARTAN WAS INITIALLY APPROVED SEPTEMBER 9TH, 2010 IN SOUTH KOREA AND IS MARKETED UNDER THE BRAND NAME KANARB BY BORYUNG PHARMACEUTICALS.
PHARMACODYNAMICS
FIMASARTAN IS A SELECTIVE ANGIOTENSIN RECEPTOR 1 (AR1) INHIBITOR . IT ACTS TO LOWER BLOOD PRESSURE BY INHIBITING VASOCONSTRICTION
MECHANISM OF ACTION
ANGIOTENSIN II ACTIVATES AR1 LEADING TO VASOCONSTRICTION AND INCREASED NORADRENALINE RELEASE WHICH FURTHER INCREASES VASOCONSTRICTION VIA ACTION AT ?1-ADRENERGIC RECEPTORS ,. IT ALSO STIMULATES SECRETION OF ALDOSTERONE WHICH ACTS TO INCREASE SODIUM AND WATER REABSORPTION IN THE RENAL TUBULES . FIMASARTAN BIND TO AND ANTAGONIZES AR1 PREVENTING VASOCONSTRICTION AND REDUCING ALDOSTERONE SECRETION TO INCREASE NATRIURESIS LEADING TO A REDUCTION IN BLOOD VOLUME. TOGETHER THESE EFFECTS PRODUCE AN ANTI-HYPERTENSIVE EFFECT.
ABEMACICLIB ABEMACICLIB MAY DECREASE THE EXCRETION RATE OF FIMASARTAN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ACEBUTOLOL THE RISK OR SEVERITY OF HYPERKALEMIA CAN BE INCREASED WHEN ACEBUTOLOL IS COMBINED WITH FIMASARTAN.
ACECLOFENAC THE RISK OR SEVERITY OF RENAL FAILURE, HYPERKALEMIA, AND HYPERTENSION CAN BE INCREASED WHEN FIMASARTAN IS COMBINED WITH ACECLOFENAC.
ACEMETACIN THE RISK OR SEVERITY OF RENAL FAILURE, HYPERKALEMIA, AND HYPERTENSION CAN BE INCREASED WHEN FIMASARTAN IS COMBINED WITH ACEMETACIN.
ACETYLCYSTEINE THE EXCRETION OF FIMASARTAN CAN BE DECREASED WHEN COMBINED WITH ACETYLCYSTEINE.
ACETYLSALICYLIC ACID THE RISK OR SEVERITY OF RENAL FAILURE, HYPERKALEMIA, AND HYPERTENSION CAN BE INCREASED WHEN FIMASARTAN IS COMBINED WITH ACETYLSALICYLIC ACID.
AFATINIB AFATINIB MAY DECREASE THE EXCRETION RATE OF FIMASARTAN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
AGMATINE THE RISK OR SEVERITY OF HYPERKALEMIA CAN BE INCREASED WHEN AGMATINE IS COMBINED WITH FIMASARTAN.
ALCLOFENAC THE RISK OR SEVERITY OF RENAL FAILURE, HYPERKALEMIA, AND HYPERTENSION CAN BE INCREASED WHEN FIMASARTAN IS COMBINED WITH ALCLOFENAC.
ALDESLEUKIN THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ALDESLEUKIN IS COMBINED WITH FIMASARTAN.
ALECTINIB ALECTINIB MAY DECREASE THE EXCRETION RATE OF FIMASARTAN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ALISKIREN THE RISK OR SEVERITY OF HYPERKALEMIA CAN BE INCREASED WHEN ALISKIREN IS COMBINED WITH FIMASARTAN.
ALMINOPROFEN THE RISK OR SEVERITY OF RENAL FAILURE, HYPERKALEMIA, AND HYPERTENSION CAN BE INCREASED WHEN FIMASARTAN IS COMBINED WITH ALMINOPROFEN.
ALPRENOLOL THE RISK OR SEVERITY OF HYPERKALEMIA CAN BE INCREASED WHEN ALPRENOLOL IS COMBINED WITH FIMASARTAN.
AMBRISENTAN THE THERAPEUTIC EFFICACY OF AMBRISENTAN CAN BE INCREASED WHEN USED IN COMBINATION WITH FIMASARTAN.
AMIFOSTINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN AMIFOSTINE IS COMBINED WITH FIMASARTAN.
AMILORIDE THE RISK OR SEVERITY OF HYPERKALEMIA CAN BE INCREASED WHEN FIMASARTAN IS COMBINED WITH AMILORIDE.
AMINOHIPPURIC ACID THE EXCRETION OF FIMASARTAN CAN BE DECREASED WHEN COMBINED WITH AMINOHIPPURIC ACID.
AMINOPHENAZONE THE RISK OR SEVERITY OF RENAL FAILURE, HYPERKALEMIA, AND HYPERTENSION CAN BE INCREASED WHEN FIMASARTAN IS COMBINED WITH AMINOPHENAZONE.
AMIODARONE THE RISK OR SEVERITY OF HYPERKALEMIA CAN BE INCREASED WHEN AMIODARONE IS COMBINED WITH FIMASARTAN.
AMLODIPINE THE RISK OR SEVERITY OF HYPERKALEMIA CAN BE INCREASED WHEN AMLODIPINE IS COMBINED WITH FIMASARTAN.
AMMONIUM CHLORIDE THE RISK OR SEVERITY OF HYPERKALEMIA CAN BE INCREASED WHEN AMMONIUM CHLORIDE IS COMBINED WITH FIMASARTAN.
AMOBARBITAL AMOBARBITAL MAY INCREASE THE HYPOTENSIVE ACTIVITIES OF FIMASARTAN.
AMPHETAMINE AMPHETAMINE MAY INCREASE THE ORTHOSTATIC HYPOTENSIVE ACTIVITIES OF FIMASARTAN.
AMPHOTERICIN B THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN AMPHOTERICIN B IS COMBINED WITH FIMASARTAN.
AMPRENAVIR THE EXCRETION OF FIMASARTAN CAN BE DECREASED WHEN COMBINED WITH AMPRENAVIR.
AMYL NITRITE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN AMYL NITRITE IS COMBINED WITH FIMASARTAN.
ANGIOTENSIN 1-7 THE THERAPEUTIC EFFICACY OF ANGIOTENSIN 1-7 CAN BE INCREASED WHEN USED IN COMBINATION WITH FIMASARTAN.
ANISODAMINE THE RISK OR SEVERITY OF HYPERKALEMIA CAN BE INCREASED WHEN FIMASARTAN IS COMBINED WITH ANISODAMINE.
ANTIPYRINE THE RISK OR SEVERITY OF RENAL FAILURE, HYPERKALEMIA, AND HYPERTENSION CAN BE INCREASED WHEN FIMASARTAN IS COMBINED WITH ANTIPYRINE.
ANTRAFENINE THE RISK OR SEVERITY OF RENAL FAILURE, HYPERKALEMIA, AND HYPERTENSION CAN BE INCREASED WHEN FIMASARTAN IS COMBINED WITH ANTRAFENINE.
APALUTAMIDE THE EXCRETION OF FIMASARTAN CAN BE INCREASED WHEN COMBINED WITH APALUTAMIDE.
APOMORPHINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN APOMORPHINE IS COMBINED WITH FIMASARTAN.
ARANIDIPINE THE RISK OR SEVERITY OF HYPERKALEMIA CAN BE INCREASED WHEN ARANIDIPINE IS COMBINED WITH FIMASARTAN.
ARDEPARIN THE RISK OR SEVERITY OF HYPERKALEMIA CAN BE INCREASED WHEN ARDEPARIN IS COMBINED WITH FIMASARTAN.
ARIPIPRAZOLE ARIPIPRAZOLE MAY INCREASE THE HYPOTENSIVE ACTIVITIES OF FIMASARTAN.
ARIPIPRAZOLE LAUROXIL ARIPIPRAZOLE LAUROXIL MAY INCREASE THE HYPOTENSIVE ACTIVITIES OF FIMASARTAN.
AROTINOLOL THE RISK OR SEVERITY OF HYPERKALEMIA CAN BE INCREASED WHEN AROTINOLOL IS COMBINED WITH FIMASARTAN.
ARSENIC TRIOXIDE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ARSENIC TRIOXIDE IS COMBINED WITH FIMASARTAN.
ASUNAPREVIR THE EXCRETION OF FIMASARTAN CAN BE DECREASED WHEN COMBINED WITH ASUNAPREVIR.
ATAZANAVIR THE EXCRETION OF FIMASARTAN CAN BE DECREASED WHEN COMBINED WITH ATAZANAVIR.
ATENOLOL THE RISK OR SEVERITY OF HYPERKALEMIA CAN BE INCREASED WHEN ATENOLOL IS COMBINED WITH FIMASARTAN.
ATORVASTATIN THE EXCRETION OF FIMASARTAN CAN BE DECREASED WHEN COMBINED WITH ATORVASTATIN.
AVATROMBOPAG AVATROMBOPAG MAY DECREASE THE EXCRETION RATE OF FIMASARTAN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
AXITINIB THE EXCRETION OF FIMASARTAN CAN BE DECREASED WHEN COMBINED WITH AXITINIB.
AZAPROPAZONE THE RISK OR SEVERITY OF RENAL FAILURE, HYPERKALEMIA, AND HYPERTENSION CAN BE INCREASED WHEN FIMASARTAN IS COMBINED WITH AZAPROPAZONE.
AZELNIDIPINE THE RISK OR SEVERITY OF HYPERKALEMIA CAN BE INCREASED WHEN AZELNIDIPINE IS COMBINED WITH FIMASARTAN.
AZILSARTAN MEDOXOMIL THE RISK OR SEVERITY OF RENAL FAILURE, HYPOTENSION, AND HYPERKALEMIA CAN BE INCREASED WHEN AZILSARTAN MEDOXOMIL IS COMBINED WITH FIMASARTAN.
BALSALAZIDE THE RISK OR SEVERITY OF RENAL FAILURE, HYPERKALEMIA, AND HYPERTENSION CAN BE INCREASED WHEN FIMASARTAN IS COMBINED WITH BALSALAZIDE.
|